{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:39Z","timestamp":1786358319517,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1067\/mhj.2002.120767","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"205-216","source":"Crossref","is-referenced-by-count":12,"title":["Persistence of the prothrombotic state after acute coronary syndromes: Implications for treatment"],"prefix":"10.1067","volume":"143","author":[{"given":"Maria Cecilia","family":"Bahit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"II Suppl","key":"10.1067\/mhj.2002.120767_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0140-6736(99)90234-9","article-title":"Acute coronary syndromes: biology","volume":"353","author":"Fuster","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/01.CIR.97.12.1195","article-title":"Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction","volume":"97","author":"Theroux","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","article-title":"Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995","volume":"94","author":"Davies","year":"1996","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.CIR.97.1.26","article-title":"Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis","volume":"97","author":"Van Belle","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1161\/01.ATV.20.9.2162","article-title":"In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris","volume":"20","author":"Merlini","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1067\/mhj.2002.120767_bib8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0735-1097(98)00635-4","article-title":"Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial","volume":"33","author":"Ault","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.101.5.570","article-title":"Recognition of the importance of embolization in atherosclerotic vascular disease","volume":"101","author":"Topol","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJM199610313351801","article-title":"Cardiac troponin levels for risk stratification in acute myocardial ischemia","volume":"335","author":"Ohman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(99)10285-X","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban","volume":"354","author":"Heeschen","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin levels","volume":"340","author":"Hamm","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","article-title":"Long-term molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study","volume":"354","author":"FRISC Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1067\/mhj.2002.120767_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","article-title":"Reactivation of unstable angina after discontinuation of heparin","volume":"327","author":"Theroux","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","article-title":"Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial","volume":"93","author":"Granger","year":"1996","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0735-1097(97)00539-1","article-title":"Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I trial","volume":"31","author":"Granger","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0735-1097(01)01143-3","article-title":"Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb","volume":"37","author":"Bahit","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib19","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/oxfordjournals.eurheartj.a015467","article-title":"A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomised, dose-finding study","volume":"18","author":"TRIM Study Group","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1067\/mhj.2002.120767_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/euhj.1998.1336","article-title":"The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease","volume":"20","author":"Linder","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1067\/mhj.2002.120767_bib21","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0002-8703(98)70170-X","article-title":"Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina","volume":"136","author":"Mombelli","year":"1998","journal-title":"Am Heart J"},{"key":"10.1067\/mhj.2002.120767_bib22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.ATV.17.7.1325","article-title":"Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes","volume":"17","author":"Merlini","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1067\/mhj.2002.120767_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0735-1097(99)00322-8","article-title":"Thrombin generation after abrupt cessation of intervenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombic potential","volume":"34","author":"Becker","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/01.CIR.91.7.1929","article-title":"Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes","volume":"91","author":"Granger","year":"1995","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1055\/s-0037-1614931","article-title":"Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease","volume":"79","author":"Ernofsson","year":"1998","journal-title":"Thromb Hemost"},{"key":"10.1067\/mhj.2002.120767_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0735-1097(00)01143-8","article-title":"Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes: PURSUIT Investigators","volume":"37","author":"Greenbaum","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib27","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","author":"ISIS-2 Second International Study of Infarct Survival Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"RISC Group","year":"1990","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1067\/mhj.2002.120767_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease: FRISC Study Group. Fragmin during Instability in Coronary Artery Disease","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","article-title":"Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia","volume":"26","author":"Gurfinkel","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low molecular heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib36","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1067\/mhj.2002.120767_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","author":"Fragmin during Instability in Coronary Artery Disease FRISC Study Group","year":"1996","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib39","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib40","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0140-6736(99)07349-3","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib42","first-page":"499","article-title":"Effect of long term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction","volume":"343","author":"Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis ASPECT Research Group","year":"1994","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJM199007193230302","article-title":"The effect of warfarin on mortality and reinfarction after myocardial infarction","volume":"323","author":"Smith","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib44","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1161\/01.CIR.98.11.1064","article-title":"Long term oral anticoagulant therapy in patients with unstable angina or suspected non Q wave myocardial Infarction: OASIS pilot study results","volume":"98","author":"Anand","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib45","first-page":"396A","article-title":"The OASIS investigators: randomised trial of oral anticoagulant therapy in patients with acute ischemic syndromes without ST elevation: importance of good compliance","volume":"33","author":"Anand","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomized double-blind trial of fixed low dose warfarin with aspirin after myocardial infarction","volume":"350","author":"Coumadin Aspirin Reinfarction Study CARS Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib47","series-title":"Plenary Session XII: Late Breaking Clinical Trials. Proceedings of the 72nd Scientific Sessions of the American Heart Association; 1999 Nov 7-10; Atlanta, Ga","author":"Fiore","year":"1999"},{"key":"10.1067\/mhj.2002.120767_bib48","article-title":"The Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2)","author":"Van Es","year":"2000"},{"key":"10.1067\/mhj.2002.120767_bib49","article-title":"The Antithrombotics in the Prevention of Reocclusion in Coronary Thrombosis-2 (APRICOT-2)","author":"Brower","year":"2000"},{"key":"10.1067\/mhj.2002.120767_bib50","series-title":"Proceedings of the 23rd Congress of the European Society of Cardiology; 2001 Sept 2-5; Stockholm, Sweden","author":"Arnesen","year":"2001"},{"key":"10.1067\/mhj.2002.120767_bib51","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Investigators","year":"1996","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib52","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"CURE Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","article-title":"Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib55","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization","volume":"342","author":"O'Neill","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120767_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orbofiban with unstable coronary syndromes (OPUS TIMI 16) trial","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial","volume":"355","author":"SYMPHONY Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120767_bib58","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.103.13.1727","article-title":"Randomized trial of aspirin, sibrafiban or both for secondary prevention after acute coronary syndromes","volume":"103","author":"Second SYMPHONY Investigators","year":"2001","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1067\/mhj.2000.105107","article-title":"Design of the Blockade of the Glycoprotein IIb\/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial","volume":"139","author":"Topol","year":"2000","journal-title":"Am Heart J"},{"key":"10.1067\/mhj.2002.120767_bib60","article-title":"Increased expression of platelet P-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 trial","author":"Casey","year":"1999"},{"key":"10.1067\/mhj.2002.120767_bib61","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1074\/jbc.275.8.5760","article-title":"Glycoprotein IIb\/IIIa antagonist induce apoptosis in rat cardiomyocytes by Caspase-3 activation","volume":"275","author":"Adderley","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1067\/mhj.2002.120767_bib62","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0002-8703(97)70164-9","article-title":"Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators","volume":"133","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1067\/mhj.2002.120767_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","article-title":"Troponin T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection","volume":"29","author":"Lindahl","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120767_bib64","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","article-title":"Benefit of glycoprotein IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B troponin T substudy","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120767_bib65","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030265464X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030265464X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T01:46:01Z","timestamp":1576460761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287030265464X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S000287030265464X"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2002.120767","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}